These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26511203)

  • 1. B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.
    Homann A; Röckendorf N; Kromminga A; Frey A; Jappe U
    J Transl Med; 2015 Oct; 13():339. PubMed ID: 26511203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.
    Homann A; Röckendorf N; Kromminga A; Frey A; Platts-Mills TA; Jappe U
    Theranostics; 2017; 7(19):4699-4709. PubMed ID: 29187897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
    Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab.
    Kosmač M; Avčin T; Toplak N; Simonini G; Cimaz R; Curin Šerbec V
    Pediatr Res; 2011 Mar; 69(3):243-8. PubMed ID: 21131896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-52 kDa Ro(SSA) autoantibodies in different autoimmune diseases preferentially recognize epitopes on the central region of the antigen.
    Dorner T; Feist E; Wagenmann A; Kato T; Yamamoto K; Nishioka K; Burmester GR; Hiepe F
    J Rheumatol; 1996 Mar; 23(3):462-8. PubMed ID: 8832984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-target activity of TNF-alpha inhibitors characterized by protein biochips.
    Feyen O; Lueking A; Kowald A; Stephan C; Meyer HE; Göbel U; Niehues T
    Anal Bioanal Chem; 2008 Jul; 391(5):1713-20. PubMed ID: 18344017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
    Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
    Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
    Krintel SB; Grunert VP; Hetland ML; Johansen JS; Rothfuss M; Palermo G; Essioux L; Klause U
    Rheumatology (Oxford); 2013 Jul; 52(7):1245-53. PubMed ID: 23459699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.